Breaking News, Collaborations & Alliances

Alchemab & Lilly Partner to Discover Novel Therapies for ALS

Will collaborate to discover, develop, and commercialize up to five novel therapeutics.

Author Image

By: Charlie Sternberg

Associate Editor

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, has entered a collaboration with Lilly to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS). Alchemab’s technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience. Alchemab believes these antibodies, which a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics